Miklos Argyelan

Miklos Argyelan

Auto-generated profile, based on publicly available information

Miklos Argyelan

Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
DSDeepak K. Sarpal
Deepak K. Sarpal
DRDelbert G. Robinson
Delbert G. Robinson
TLTodd Lencz
Todd Lencz
MAMiklos Argyelan
Miklos Argyelan
Toshikazu IkutaToshikazu Ikuta
Toshikazu Ikuta
AMAnil K. Malhotra
Anil K. Malhotra
Disruptions in corticostriatal circuitry have been implicated in the pathophysiology of schizophrenia. Early proposals linked schizophrenia with decreases in dopamine in the prefrontal cortex and excessive dopamine in the striatum.1,2 Although elevated striatal dopamine has been shown in patients with schizophrenia,3 their unaffected relatives,4 and individuals who are at risk for developing psychotic symptoms,5 corticostriatal relationships have also been demonstrated to play a central role in psychosis. Early positron emission tomography work found that the severity of psychotic symptoms correlated with abnormal patterns of blood flow in limbic and prefrontal cortical regions.6 Studies in schizophrenia using functional magnetic resonance imaging (fMRI) have reported abnormal corticostriatal activation during reward7,8 and executive processing.9,10 Evidence from functional connectivity and multimodal studies have shown altered corticostriatal circuitry in patients with chronic schizophrenia11,12 and in patients with prodromal psychotic symptoms.13,14 A previous family-based study suggested that altered functional connectivity between striatum and cortical regions may represent a risk phenotype in patients with first-episode psychosis (FEP) and their relatives.15

5 August 2009 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MAMiklos Argyelan
Miklos Argyelan
MCMaren Carbon
Maren Carbon
MNMartin Niethammer
Martin Niethammer
AUAziz M. Uluğ
Aziz M. Uluğ
HVHenning U. Voss
Henning U. Voss
DEDavid Eidelberg
David Eidelberg
Dystonia is a brain disorder characterized by sustained involuntary muscle contractions. It is typically inherited as an autosomal dominant trait with incomplete penetrance. While lacking clear degenerative neuropathology, primary dystonia is thought to involve microstructural and functional changes in neuronal circuitry. In the current study, we used magnetic resonance diffusion tensor imaging and probabilistic tractography to identify the specific circuit abnormalities that underlie clinical penetrance in carriers of genetic mutations for this disorder. This approach revealed reduced integrity of cerebellothalamocortical fiber tracts, likely developmental in origin, in both manifesting and clinically nonmanifesting dystonia mutation carriers. In these subjects, reductions in cerebellothalamic connectivity correlated with increased motor activation responses, consistent with loss of inhibition at the cortical level. Nonmanifesting mutation carriers were distinguished by an additional area of fiber tract disruption situated distally along the thalamocortical segment of the pathway, in tandem with the proximal cerebellar outflow abnormality. In individual gene carriers, clinical penetrance was determined by the difference in connectivity measured at these two sites. Overall, these findings point to a novel mechanism to explain differences in clinical expression in carriers of genes for brain disease.

1 January 2016 in American Journal of Psychiatry
Verified
Journal Article
Closed access
DSDeepak K. Sarpal
Deepak K. Sarpal
MAMiklos Argyelan
Miklos Argyelan
DRDelbert G. Robinson
Delbert G. Robinson
PSPhilip R. Szeszko
Philip R. Szeszko
KKKatherine H. Karlsgodt
Katherine H. Karlsgodt
AMAnil K. Malhotra
Anil K. Malhotra

1 May 2011 in Neurobiology of Disease
Verified
Journal Article
Closed access
MNMartin Niethammer
Martin Niethammer
MCMaren Carbon
Maren Carbon
MAMiklos Argyelan
Miklos Argyelan
DEDavid Eidelberg
David Eidelberg

4 April 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AUAziz M. Uluğ
Aziz M. Uluğ
AVAn Vo
An Vo
MAMiklos Argyelan
Miklos Argyelan
LTLauren Tanabe
Lauren Tanabe
WSWynne K. Schiffer
Wynne K. Schiffer
DEDavid Eidelberg
David Eidelberg
The factors that determine symptom penetrance in inherited disease are poorly understood. Increasingly, magnetic resonance diffusion tensor imaging (DTI) and PET are used to separate alterations in brain structure and function that are linked to disease symptomatology from those linked to gene carrier status. One example is DYT1 dystonia, a dominantly inherited movement disorder characterized by sustained muscle contractions, postures, and/or involuntary movements. This form of dystonia is caused by a 3-bp deletion (i.e., ΔE) in theTOR1Agene that encodes torsinA. Carriers of the DYT1 dystonia mutation, even if clinically nonpenetrant, exhibit abnormalities in cerebellothalamocortical (CbTC) motor pathways. However, observations in human gene carriers may be confounded by variability in genetic background and age. To address this problem, we implemented a unique multimodal imaging strategy in a congenic line of DYT1 mutant mice that contain the ΔE mutation in the endogenous mouse torsinA allele (i.e., DYT1 knock-in). Heterozygous knock-in mice and littermate controls underwent microPET followed by ex vivo high-field DTI and tractographic analysis. Mutant mice, which do not display abnormal movements, exhibited significant CbTC tract changes as well as abnormalities in brainstem regions linking cerebellar and basal ganglia motor circuits highly similar to those identified in human nonmanifesting gene carriers. Moreover, metabolic activity in the sensorimotor cortex of these animals was closely correlated with individual measures of CbTC pathway integrity. These findings further link a selective brain circuit abnormality to gene carrier status and demonstrate that DYT1 mutant torsinA has similar effects in mice and humans.

1 March 2020 in Biological Psychiatry
Verified
Journal Article
Open access
OOOlga Therese Ousdal
Olga Therese Ousdal
MAMiklos Argyelan
Miklos Argyelan
KNKatherine L. Narr
Katherine L. Narr
CAChristopher C. Abbott
Christopher C. Abbott
BWBenjamin Wade
Benjamin Wade
PSPascal Sienaert
Pascal Sienaert
Electroconvulsive therapy (ECT) is associated with volumetric enlargements of corticolimbic brain regions. However, the pattern of whole-brain structural alterations following ECT remains unresolved. Here, we examined the longitudinal effects of ECT on global and local variations in gray matter, white matter, and ventricle volumes in patients with major depressive disorder as well as predictors of ECT-related clinical response. Longitudinal magnetic resonance imaging and clinical data from the Global ECT-MRI Research Collaboration (GEMRIC) were used to investigate changes in white matter, gray matter, and ventricle volumes before and after ECT in 328 patients experiencing a major depressive episode. In addition, 95 nondepressed control subjects were scanned twice. We performed a mega-analysis of single subject data from 14 independent GEMRIC sites. Volumetric increases occurred in 79 of 84 gray matter regions of interest. In total, the cortical volume increased by mean ± SD of 1.04 ± 1.03% (Cohen's d = 1.01, p < .001) and the subcortical gray matter volume increased by 1.47 ± 1.05% (d = 1.40, p < .001) in patients. The subcortical gray matter increase was negatively associated with total ventricle volume (Spearman's rank correlation ρ = -.44, p < .001), while total white matter volume remained unchanged (d = -0.05, p = .41). The changes were modulated by number of ECTs and mode of electrode placements. However, the gray matter volumetric enlargements were not associated with clinical outcome. The findings suggest that ECT induces gray matter volumetric increases that are broadly distributed. However, gross volumetric increases of specific anatomically defined regions may not serve as feasible biomarkers of clinical response.